Yahoo Finance

RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $447 from $477 and keeps an Outperform rating on the shares. The company reported a slight miss for Q4, with guidance coming in below consensus estimates on the top and bottom line, though based on peers’ results thus far, the low-single-digit top-line guide is not a major surprise, the analyst tells investors in a research note. RBC adds however that the lack of meaningful margin expansion by Bio-Rad was still surprising.

Discover the Best Stocks and Maximize Your Portfolio:

• See what stocks are receiving strong buy ratings from top-rated analysts.

• Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on BIO:

• Bio-Rad Laboratories Reports 2024 Earnings and Strategic Plans

• Bio-Rad reports Q4 adjusted EPS $2.90, consensus $2.88

• Bio-Rad sees FY25 currency neutral revenue growth 1.5%-3.5%

• Bio-Rad to acquire Stilla Technologies

• Bio-Rad price target lowered to $345 from $360 at Wells Fargo